Cannabis Law Report

JUNE 4, 2021

. – Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Investor Contact: Robert Schatz.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. During the trial, patients with focal seizures (n=19) showed a median 25.2 We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We On July 30, 2021, Virpax announced the appointment of Gerald W. On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. million as of September 30, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. Our next series of MDT webinars on cannabis for symptom management in oncology takes place on March 29, 2021.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

DECEMBER 9, 2021

Thu, December 9, 2021, . 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

OCTOBER 1, 2021

Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time. www.youtube.com/channelchek. About Virpax Pharmaceuticals. About Channelchek.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

JUNE 7, 2021

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. For more information, visit www.mymd.com.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

NOVEMBER 12, 2021

Released 07:00:14 01 November 2021. 01 November 2021. 1 November 2021. of the voting rights of KCP in the Company) that on 1 July 2021, KCP was offered a facility of £1,000,000 by Brown Shipley & Co Limited (“Brown Shipley”) by way of an overdraft (the “Facility”). RNS Number : 8293Q.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. Stolar & Ilan Matok. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

SEPTEMBER 2, 2021

Testing is scheduled to begin in the second half of September 2021. The College, part of the State University of New York (SUNY) system, is aligned with SUNY’s vaccination mandate, which requires all on-campus students to be fully vaccinated against COVID-19 by September 27, 2021. Hayward, president and CEO of Applied DNA. “As

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. Fiscal 2021 Third Quarter Financial Results and Investor Conference Call. Food and Drug Administration (U.S.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. 3 Nature Aging | VOL 1 | July 2021 | p. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

2021 Aug 26;23:119-127. eCollection 2021 Dec 10. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. doi: 10.1016/j.omtm.2021.08.006.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

OCTOBER 12, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Testing began this week and is available to asymptomatic students, faculty, and staff on a voluntary basis. Food and Drug Administration (U.S.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 28, 2021

Advance to FDA IND-enabling studies to support human clinical studies. – July 28, 2021) – PharmaDrug Inc. The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

DECEMBER 21, 2021

SAN DIEGO–(BUSINESS WIRE)– $DFCO #CleanEnergy — Dalrada Corporation (OTCQB: DFCO , “Dalrada”) would like to express its sincere appreciation for its investors, shareholders, staff and followers for their support throughout 2021. from 2021 to 2028. from 2021 to 2030. billion (2020).

Research and Development 52

Research and Development Supply Chain Data Business 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Nov 24 2021. Journal of Clinical Gynecology and Obstetrics, North Amer, 0 Nov 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 10, 2021

In October 2021, Virpax announced that a $1.87 Also, the NIH engaged Battelle to conduct Dose Range Finding Studies, with the first study in rats being completed on October 7 th , 2021. A Dose Range Finding Study in dogs will start on November 10, 2021. A Dose Range Finding Study in dogs will start on November 10, 2021.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Prior to this Transaction, KWC has grown without taking outside capital.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. During his career, Dr. McLin has supported the launch of six products at start-up and mid-size pharmaceutical companies, where he has identified innovative, data-driven opportunities to engage patients, prescribers, and payers.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52